Four things to know:
1. Significant investments from Mitsubishi UFJ Capital, DiscGenics’ board of directors and existing long-term investors contributed to the oversubscription of the round.
2. DiscGenics has secured more than $71 million in funding to date.
3. The company will use the funds to support clinical trials of its allogeneic, injectable disc cell therapy for lumbar degenerative disc disease.
4. DiscGenics has added two new board members and plans to expand out of its manufacturing facility in Salt Lake City.
More articles on biologics:
Medtronic Q1 spine revenue down 14% to $1.8B; CEO reports ‘faster than expected recovery’
Dr. Richard Berger: Potential for delays makes now ‘the best time to get surgery’
Total Orthopedics Sports & Spine, American Airlines gain EPA approval for COVID-19 surface cleanser
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.